Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingPRNewsWire • 05/02/24
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthPRNewsWire • 04/29/24
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/24
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/25/24
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationPRNewsWire • 03/21/24
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 ConferencePRNewsWire • 03/20/24
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024PRNewsWire • 03/12/24
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional TestimonyPRNewsWire • 02/15/24
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility StudiesPRNewsWire • 12/12/23
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock SplitPRNewsWire • 12/04/23
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting EffortsPRNewsWire • 11/16/23
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor DayPRNewsWire • 11/09/23
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services ForumPRNewsWire • 11/02/23
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer DetectionPRNewsWire • 10/31/23
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023PRNewsWire • 10/31/23
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare ConferencePRNewsWire • 09/21/23
PAVmed and Lucid Diagnostics - to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare ConferencePRNewsWire • 09/21/23
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer DetectionPRNewsWire • 09/07/23
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire FightersPRNewsWire • 09/06/23